Catalyst
Slingshot members are tracking this event:
Agios Pharma (AGIO) to Complete Phase 1 study of AG-120 in Subjects With Advanced Solid Tumors with an IDH1 Mutation in August 2017
Do you think this event is important to the companies below? How will it affect their stock price?
Additional Information
Present data from the expansion phase of the ongoing Phase 1 study of AG-120 in advanced IDH1 mutant positive low-grade glioma in the second half of 2016
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 03, 2017
Occurred Source:
http://investor.agios.com/news-releases/news-release-details/agios-presents-phase-1-data-dose-escalation-and-expansion-0
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Glioma, Solid Tumor Cancer, Idh1 Inhibitor, Phase 1 Study, Ag-120, Orphan Drug, Fast Track Status, Chondrosarcoma, Carcinoma
